A Canadian cannabis producer is moving forward with the acquisition of an official Mexican company capable to import medical cannabis products.

On Monday (December 10), Aurora Cannabis (NYSE:ACB,TSX:ACB) formalized its entry to the Mexican market by announcing a complete acquisition of Farmacias Magistrales, a pharmaceutical laboratory based in Mexico City.

The Canadian licensed producer (LP) will complete this purchase through its own shares at a price not yet confirmed, set to be determined “on a valuation of the proforma distribution revenue projections of Farmacias.”

Neil Belot, chief global business development officer for Aurora, said the company was impressed with the quality of assets and operations from Farmacias Magistrales.

Aurora’s interest in the Mexican venture comes after the LP confirmed an exclusive partnership to import Aurora’s medical cannabis product.

On the benefits of the acquisition, Aurora said:

Farmacias recently became Mexico’s first and only federally licensed importer to date of raw materials containing [tetrahydrocannabinol] THC, gaining the necessary licenses, facilities, and permissions to import raw THC material, and manufacture, store, and distribute medical cannabis products containing over 1 [percent] THC

For both announcements, Aurora touted the advantage of a legal market with 130 million people in it.

“Farmacias has a large distribution network of both retail outlets and pharmacies, which will enable us to quickly scale up our operations across Mexico,” Aurora CEO Terry Booth said.

Shares of Aurora opened on Monday at a price of C$7.80 in Toronto while in New York the company started the day with a US$5.90 price. Near the end of the trading session Aurora stock was marginally down in both exchanges.

While Aurora’s deal is for a position in the medical marijuana market, Mexico made headlines in November when it was reported incoming interior minister Senator Olga Sanchéz would be introducing legislation for the drug.

The legislation was introduced after the Mexican Supreme Court ruled in favor of two new cannabis cases, which created a new standard in Mexican law to abide by.

“From a point of view of the negative side effects, there isn’t any reason for which cannabis isn’t illegal, while alcohol and tobacco are,” an early version of the bill from Mexican leading party Morena indicated.

Aurora isn’t the only company to have announced plans for the Mexican market, with fellow LPs competing for a position additionally in the overall Latin American space.

Canopy Growth (NYSE:CGC,TSX:WEED), Tilray (NASDAQ:TLRY) and Aphria (NYSE:APHA,TSX:APHA) have all recently made announcements on their respective Latin American expansions.

Aphria’s expansion plans have recently come under scrutiny as the company was targeted by a short seller report based on the method it went about acquiring these assets.

Khiron Life Sciences (TSXV:KHRN), a Colombia-based cannabis company, has also secured a spot in the Mexican market with the import and commercialization of three products from its nutraceutical line.

The company obtained this entry thanks to its subsidiary, Kuida Life Mexico, getting approval from Mexico’s Federal Commission for the Protection against Sanitary Risk, the authority on cannabis products.

Former Mexican president Vicente Fox, who made his own entry into the cannabis space as a board member for Khiron, said the steps Mexico has taken to legalize the adult use of cannabis have the potential to “reduce crime, increase prosperity and improve the health of our citizens.”

Don’t forget to follow us @INN_LifeScience and @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Khiron Life Sciences is a client of the Investing News Network. This article is not paid-for content.

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less


Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less